Workplace solvents may intensify Parkinson's disease

September 11, 2000

ST. PAUL, MN -- Jobs involving the use of common solvents can put people at risk for developing symptoms of Parkinson's disease earlier in life and more severe disease symptoms throughout its course, according to a study in the September 12 issue of Neurology, the scientific journal of the American Academy of Neurology.

From a study of 990 Parkinson's patients, Italian researchers found that those exposed to hydrocarbon solvents, found in common petroleum-based products such as paints and glues, were an average of three years younger at first sign of disease symptoms. The severity of disease symptoms was found to be directly related to the amount of hydrocarbon exposure that was experienced.

Researchers identified nine occupations within the study group that accounted for more than 91 percent of the hydrocarbon solvent exposure. The most common occupations of those exposed were petroleum, plastic and rubber workers. Other occupations found to have frequent hydrocarbon exposure were painters, engine mechanics and lithographers.

"These findings raise serious questions about specific occupational risk," said study author Gianni Pezzoli, MD, of the Parkinson Institute in Milan, Italy. "This study more than merits further investigation into job-related Parkinson's risk factors."

The study was designed to find differences between new patients at a Parkinson's clinic who had and had not experienced hydrocarbon exposure in their lives. The research also found that those with hydrocarbon exposure were mostly male and less educated than those who were not exposed. Parkinson's disease is a slowly progressive, neurodegenerative disease caused when a small group of brain cells die that control body movement. Symptoms generally include tremor in arms and legs, rigid muscles, slowness of movements and impaired balance. Parkinson's disease affects more than 500,000 Americans.
-end-
A neurologist is a medical doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system.

The American Academy of Neurology, an association of more than 16,000 neurologists and neuroscience professionals, is dedicated to improving patient care through education and research.

For more information about the American Academy of Neurology, visit its Web site at http://www.aan.com. For online neurological health and wellness information, visit NeuroVista at http://www.aan.com/neurovista.

For more information contact: Dan Bensman (651) 695-2789


American Academy of Neurology

Related Neurology Articles from Brightsurf:

Lancet Neurology publishes results of AFFiRiS' Phase 1 trial with PD01A in Parkinson's
AFFiRiS AG, a clinical-stage biotechnology company developing novel disease-modifying specific active immunotherapies (SAITs), today announced that detailed results of the phase 1 clinical program with its lead candidate PD01 in early Parkinson's disease (PD) patients were published in the peer-reviewed journal The Lancet Neurology

Telemedicine effective for monitoring patients in large pediatric neurology network
As the COVID-19 pandemic sent entire communities into lockdown, doctors quickly adopted telehealth strategies without knowing whether they would be effective or feasible.

The Lancet Neurology: Discovery could speed diagnosis and treatment of children with life-threatening neurological diseases
A group of life-threatening neurological conditions affecting children have been linked to an antibody which points to potential treatment, according to an observational multicentre study involving 535 children with central nervous system (CNS) demyelinating disorders and encephalitis, published in The Lancet Neurology journal.

Meaningful change in culture urged to save neurology, reduce gender gap
UC Davis School of Medicine dean, NINDS deputy director lead national charge to improve conditions for women in neurology.

BrainStorm Cell Tx publishes NurOwn ALS Phase 2 randomized trial data in neurology
Results from Brainstorm Cell Therapeutic's NurOwn randomized Phase 2 clinical trial were published in Neurology.

The Lancet Neurology: Pioneering study suggests that an exoskeleton for tetraplegia could be feasible
A whole-body exoskeleton, operated by recording and decoding brain signals, has helped a tetraplegic patient to move all four of his paralysed limbs, according to results of a 2-year trial published in The Lancet Neurology journal.

The Lancet Neurology: Frailty could make people more susceptible to dementia
New research published in The Lancet Neurology journal suggests that frailty makes older adults more susceptible to Alzheimer's dementia, and moderates the effects of dementia-related brain changes on dementia symptoms.

The Lancet Neurology: Cannabis-based drug in combination with other anti-spasticity
Oral spray containing two compounds derived from the cannabis plant reduced spasticity compared with placebo in patients already taking anti-spasticity drugs.

New neurology studies a 'wakeup call' for global health
Neurology experts from around the world will convene Nov. 27 in New Zealand for a Global Brain Summit examining what one calls 'the greatest challenge of societies in the 21st century.' Among the neurological disorders to be discussed at the Summit are stroke, traumatic brain injury, Alzheimer's disease, Parkinson's disease, multiple sclerosis, and migraine and other headaches.

The Lancet Neurology: Daily and weekly cycles of epileptic seizures more common than previously thought
Understanding the pattern of seizures, and how they are linked to circadian rhythms, could be important in improving management of epilepsy.

Read More: Neurology News and Neurology Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.